These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 9736812)
1. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812 [TBL] [Abstract][Full Text] [Related]
2. [Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies]. Kacprzyk F Pol Arch Med Wewn; 2002 Sep; 108(3):843-7. PubMed ID: 12600180 [TBL] [Abstract][Full Text] [Related]
3. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215 [TBL] [Abstract][Full Text] [Related]
4. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764 [TBL] [Abstract][Full Text] [Related]
5. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Mouawad R; Khayat D; Soubrane C Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407 [TBL] [Abstract][Full Text] [Related]
6. S-Fas urinary excretion helps to predict the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis. Zwiech R J Korean Med Sci; 2013 Oct; 28(10):1474-81. PubMed ID: 24133352 [TBL] [Abstract][Full Text] [Related]
7. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Toyoda M; Kakizaki S; Horiguchi N; Sato K; Takayama H; Takagi H; Nagamine T; Mori M Liver; 2000 Jul; 20(4):305-11. PubMed ID: 10959809 [TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure. Kinugawa T; Kato M; Yamamoto K; Hisatome I; Nohara R Int Heart J; 2012; 53(3):182-6. PubMed ID: 22790687 [TBL] [Abstract][Full Text] [Related]
9. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865 [TBL] [Abstract][Full Text] [Related]
11. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients. Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151 [TBL] [Abstract][Full Text] [Related]
12. Soluble Fas and soluble Fas-ligand in children with Escherichia coli O157:H7-associated hemolytic uremic syndrome. Masri C; Proulx F; Toledano B; Clermont MJ; Mariscalco MM; Seidman EG; Carcillo J Am J Kidney Dis; 2000 Oct; 36(4):687-94. PubMed ID: 11007669 [TBL] [Abstract][Full Text] [Related]
13. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. Lenzlinger PM; Marx A; Trentz O; Kossmann T; Morganti-Kossmann MC J Neuroimmunol; 2002 Jan; 122(1-2):167-74. PubMed ID: 11777556 [TBL] [Abstract][Full Text] [Related]
14. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. Christensson M; Pettersson E; Eneslätt K; Christensson B; Bratt J; Rantapää-Dahlqvist S; Sundqvist KG J Clin Immunol; 2002 Jul; 22(4):220-7. PubMed ID: 12148596 [TBL] [Abstract][Full Text] [Related]
15. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Ohtsuka T; Hamada M; Sasaki O; Suzuki M; Hara Y; Shigematsu Y; Ohtani T; Honda T; Hiwada K Coron Artery Dis; 1999 Jun; 10(4):221-5. PubMed ID: 10376200 [TBL] [Abstract][Full Text] [Related]
16. Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation. Hori Y; Wada H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Nishii K; Tamaki S; Nishikawa M; Deguchi K; Minami N; Shiku H Am J Hematol; 1999 May; 61(1):21-5. PubMed ID: 10331507 [TBL] [Abstract][Full Text] [Related]